Quantitative Exchange NMR-Based Analysis of Huntingtin-SH3 Interactions Suggests an Allosteric Mechanism of Inhibition of Huntingtin Aggregation
- PMID: 34137596
- PMCID: PMC8855710
- DOI: 10.1021/jacs.1c04786
Quantitative Exchange NMR-Based Analysis of Huntingtin-SH3 Interactions Suggests an Allosteric Mechanism of Inhibition of Huntingtin Aggregation
Abstract
Huntingtin polypeptides (httex1), encoded by exon 1 of the htt gene and containing an expanded polyglutamine tract, form fibrils that accumulate within neuronal inclusion bodies, resulting in the fatal neurodegenerative condition known as Huntington's disease. Httex1 comprises three regions: a 16-residue N-terminal amphiphilic domain (NT), a polyglutamine tract of variable length (Qn), and a polyproline-rich domain containing two polyproline tracts. The NT region of httex1 undergoes prenucleation transient oligomerization on the sub-millisecond time scale, resulting in a productive tetramer that promotes self-association and nucleation of the polyglutamine tracts. Here we show that binding of Fyn SH3, a small intracellular proline-binding domain, to the first polyproline tract of httex1Q35 inhibits fibril formation by both NMR and a thioflavin T fluorescence assay. The interaction of Fyn SH3 with httex1Q7 was investigated using NMR experiments designed to probe kinetics and equilibria at atomic resolution, including relaxation dispersion, and concentration-dependent exchange-induced chemical shifts and transverse relaxation in the rotating frame. Sub-millisecond exchange between four species is demonstrated: two major states comprising free (P) and SH3-bound (PL) monomeric httex1Q7, and two sparsely populated dimers in which either both subunits (P2L2) or only a single subunit (P2L) is bound to SH3. Binding of SH3 increases the helical propensity of the NT domain, resulting in a 25-fold stabilization of the P2L2 dimer relative to the unliganded P2 dimer. The P2L2 dimer, in contrast to P2, does not undergo any detectable oligomerization to a tetramer, thereby explaining the allosteric inhibition of httex1 fibril formation by Fyn SH3.
Conflict of interest statement
The authors declare no competing financial interest.
Figures







References
-
- Andresen JM; Gayan J; Djousse L; Roberts S; Brocklebank D; Cherny SS; Group US-VCR; Group HMCR; Cardon LR; Gusella JF; MacDonald ME; Myers RH; Housman DE; Wexler NS The Relationship between CAG Repeat Length and Age of Onset Differs for Huntington’s Disease Patients with Juvenile Onset or Adult Onset. Ann. Hum. Genet 2007, 71, 295–301. - PubMed
-
- Ross CA; Tabrizi SJ Huntington’s Disease: From Molecular Pathogenesis to Clinical Treatment. Lancet Neurol. 2011, 10, 83–98. - PubMed
-
- Bates GP; Dorsey R; Gusella JF; Hayden MR; Kay C; Leavitt BR; Nance M; Ross CA; Scahill RI; Wetzel R; Wild EJ; Tabrizi SJ Huntington Disease. Nat. Rev. Dis. Primers 2015, 1, 15005. - PubMed
-
- Landles C; Sathasivam K; Weiss A; Woodman B; Moffitt H; Finkbeiner S; Sun B; Gafni J; Ellerby LM; Trottier Y; Richards WG; Osmand A; Paganetti P; Bates GP Proteolysis of Mutant Huntingtin Produces an Exon 1 Fragment That Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington Disease. J. Biol. Chem 2010, 285, 8808–8823. - PMC - PubMed
-
- Sathasivam K; Neueder A; Gipson TA; Landles C; Benjamin AC; Bondulich MK; Smith DL; Faull RL; Roos RA; Howland D; Detloff PJ; Housman DE; Bates GP Aberrant Splicing of HTT Generates the Pathogenic Exon 1 Protein in Huntington Disease. Proc. Natl. Acad. Sci. U. S. A 2013, 110, 2366–2370. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous